New Australian Parkinson’s Trial Using Wearable Technology


Your opportunity to get involved in a clinical study using wearable technology.  

When you see your doctor, they usually ask how you have been. Sometimes it may be hard to remember or describe your symptoms and this is where a monitoring device may help you.

The PKG™-Watch is a wrist worn device that records your Parkinson’s symptoms and reminds you when to take your Parkinson’s disease medication as prescribed by your doctor. This recording is done at home over 7 days while you go about your day-to-day activities. The information collected by the PKG™-Watch can tell your doctor more about your movement during the day including if you are moving a bit slowly or having difficulty in performing movements. 

Shake It Up Australia Foundation is excited to be funding this project with Global Kinetics Corporation Ltd. alongside our partners at The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s Victoria.

Shake It Up Australia Foundation and The Michael J. Fox Foundation will collectively provide $250,000 to support the trial and Parkinson’s Victoria will provide $100,000 and support for the study

Clyde Campbell, Founder and CEO of Shake It Up Australia Foundation, said, “Shake It Up Australia is excited to support the PKG™ technology in this trial which brings an opportunity to use objective measurement and targets to help Australians with Parkinson’s by gaining a real-life picture of current symptoms and responses to medications. PKG™ allows the Parkinson’s patient, their Neurologist & researchers access to vital information that can make a big difference to how we deal with Parkinson’s moving forward.” 

To participate you will need to:

  • Have been diagnosed with Parkinson’s disease
  • Be aged 59-75 years
  • Be taking 4 or more doses of levodopa medication (Kinson, Madopar or Stalevo) each day.
  • Be able to travel to a study clinic

What is involved?

You will be required to attend a participating clinic on at least three occasions and as many as seven times.  Participating clinics will be available Australia wide.

You will undergo examinations and tests similar to when you visit your neurologist.  Before each visit, you will also be asked to wear a PKG watch for a week.

Based on the various tests, doctors may change your medication to improve the control of your Parkinson’s.  

The Treat-to-Target study has already commenced in a number of Australian clinical sites and will be running for 18 months.  





About the Treat-to-Target Clinical Study

For most common chronic diseases, accurate and unbiased measurement of symptoms, such as blood glucose in diabetes or blood pressure in heart disease, is critical for calibrating treatment and management decisions. Alongside measurement, “normal” or “target” ranges help to guide decisions for doctors. For example, if blood sugar is high or low relative to a target range for diabetics, different drugs or actions are recommended. Objective targets are also important for accurately assessing potential new treatments as they provide a measurable goal for clinical trials.

For Parkinson’s disease, the idea of using objective and continuous measurements and targets to improve routine care is relatively new. This landmark “Treat-to-Target” study will use the Personal KinetiGraph™ ( PKG™) and objective target ranges in a formal controlled trial to establish whether it leads to improved outcomes for people with PD. The study will recruit 225 people with PD from numerous sites across Australia, Europe and the United States and evaluate the benefits and efficacy of using objective and continuous targets over a period of 18 months.

The benefits of objective treatment targets for clinical care in PD were highlighted in a recent publication in npj Parkinson’s Disease, which serves as the foundation for the clinical design of the landmark Treat-to-Target study (


Enquire about Participating in the Study.

Learn more about other research projects currently underway in Australia